Lipodystrophy
1 paper
- Humans1
Trial sponsors
Company1 trialPhase 2100 people
1 trialPhase 440 people
1 trialPhase 430 people
1 trialPhase 420 people
National Institute of Allergy and Infectious Diseases
3 trialsPhase 3736 people
1 trialPhase 340 people
National Institute of Diabetes and Digestive and Kidney Diseases
1 trialPhase 2100 people
Latest
6 in 12 monthsFrontiers in Endocrinology
Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes
Trial in 8 peopleLiraglutide
Diabetes, Obesity & Metabolism
Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real-Life Experience From a National Reference Network
Cohort study in peopleSGLT2 inhibitors
Aging Cell
Targeting RANKL Prevents Bone Loss, Improves Muscle Function and Extends Lifespan in Progeroid Mice
Experiments in miceMuscle
ADA Scientific Sessions 2026 Abstract
Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists Compared with Leptin in a Retrospective Study of Patients with Partial Lipodystrophy
Study in peopleInterventions
GSA 2025 Abstract
Uncovering Mechanisms of NRTI Induced Cellular Senescence
Experiments in cellsMechanisms
AHA Scientific Sessions 2025 Abstract
The Artificial Intelligence-Derived Electrocardiographic Age Gap is Associated with Adverse Clinical Outcomes in Cardiac Laminopathy
Study in peopleBiomarkers
ADA Scientific Sessions 2025 Abstract
Diabetogenic Processes for Increased Insulin Resistance with Concomitant Hyperinsulinemia Are Associated with Increased Colorectal Cancer Risk
Study in peopleMechanisms
ADA Scientific Sessions 2025 Abstract
Partitioned Polygenic Risk Scores (pPRS), Relationship between Insulin Secretion and Sensitivity, and Incidence of Type 2 Diabetes (T2D) in People with Prediabetes
Trial in peopleBiomarkers